[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SA518400460B1 - مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها - Google Patents

مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها

Info

Publication number
SA518400460B1
SA518400460B1 SA518400460A SA518400460A SA518400460B1 SA 518400460 B1 SA518400460 B1 SA 518400460B1 SA 518400460 A SA518400460 A SA 518400460A SA 518400460 A SA518400460 A SA 518400460A SA 518400460 B1 SA518400460 B1 SA 518400460B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
mic
relates
macrophage inhibitory
inhibitory cytokine
Prior art date
Application number
SA518400460A
Other languages
English (en)
Inventor
لارس فوج افيرسين
هينينج ثوجيرسين
اكسيانج جاو
هونجتاو جوان
سيباستين بيك جورجينسين
اكسيجيا زهانج
اوروم كريستين ساس-
بير نورجارد
كريستين تاج هانسين
وى وانج
Original Assignee
نوفو نورديسك ايه / اس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوفو نورديسك ايه / اس filed Critical نوفو نورديسك ايه / اس
Publication of SA518400460B1 publication Critical patent/SA518400460B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع بمركبات سيتوكين 1 المثبط للخلايا البلعمية Macrophage Inhibitory Cytokine-1 (MIC-1). وبشكل أخص يتعلق بمركبات مشتملة على بولي ببتيد polypeptide سيتوكين 1 المثبط للخلايا البلعمية وامتداد الحمض الأميني amino acid للنهاية N، حيث يتكون الامتداد المذكور من 3 إلى 36 جزء حمض أميني وحيث يكون لدى المركب نقطة تساوي الجهد الكهربائيIsoelectric point ((pI محسوبة أقل من 6.5. ويكون لدى مركبات الاختراع نشاط سيتوكين 1 المثبط للخلايا البلعمية. يتعلق الاختراع أيضا بتركيبات دوائية مشتملة على مثل تلك المركبات والسواغات excipients المقبولة دوائيا، بالإضافة إلى الاستخدام الطبي للمركبات. شكل5
SA518400460A 2016-05-24 2018-11-19 مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها SA518400460B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016083104 2016-05-24
CN2016103574 2016-10-27
PCT/EP2017/062583 WO2017202936A1 (en) 2016-05-24 2017-05-24 Mic-1 compounds and use thereof

Publications (1)

Publication Number Publication Date
SA518400460B1 true SA518400460B1 (ar) 2022-09-21

Family

ID=59009675

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400460A SA518400460B1 (ar) 2016-05-24 2018-11-19 مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها

Country Status (18)

Country Link
US (3) US20190248852A1 (ar)
EP (1) EP3463412A1 (ar)
JP (1) JP7013390B2 (ar)
KR (1) KR102433503B1 (ar)
CN (1) CN109414471A (ar)
AU (1) AU2017269496B2 (ar)
BR (1) BR112018072034A2 (ar)
CA (1) CA3025251A1 (ar)
CL (1) CL2018003319A1 (ar)
CO (1) CO2018012258A2 (ar)
IL (1) IL262926A (ar)
MA (1) MA45113A (ar)
MX (1) MX2018014023A (ar)
PE (1) PE20190117A1 (ar)
PH (1) PH12018502465A1 (ar)
SA (1) SA518400460B1 (ar)
TW (1) TW201741333A (ar)
WO (1) WO2017202936A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2018102854A1 (en) 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
SG11202009884YA (en) 2018-04-09 2020-11-27 Amgen Inc Growth differentiation factor 15 fusion proteins
US20210340205A1 (en) 2018-08-10 2021-11-04 Novartis Ag Gfral extracellular domains and methods of use
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2022089435A1 (en) * 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1152942C (zh) 2000-05-30 2004-06-09 华东理工大学 含载流子传输功能团的分子扭曲型电致发光材料及其应用
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
SI2441466T1 (sl) 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
ES2332100T3 (es) 2004-05-13 2010-01-26 Eli Lilly And Company Proteinas de fusion del fgf-21.
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
US7858338B2 (en) 2006-10-13 2010-12-28 Novo Nordisk Health Care Ag Processing enzymes fused to basic protein tags
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
PL2393828T3 (pl) * 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EA201491413A1 (ru) 2012-01-26 2015-03-31 Эмджен Инк. Полипептиды фактора роста и дифференцировки 15 (gdf-15)
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
MY192917A (en) 2014-07-30 2022-09-15 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
CA2961587A1 (en) 2014-10-31 2016-05-06 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PT3236991T (pt) 2014-12-23 2019-09-06 Novo Nordisk As Derivados de fgf21 e usos dos mesmos
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2017005765A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
LT3355919T (lt) 2015-10-02 2023-02-10 Julius-Maximilians-Universität Würzburg Kompleksinė terapija, panaudojant žmogaus augimo ir diferenciacijos faktoriaus 15 (gdf-15) inhibitorius ir imuninio kontrolinio taško blokatorius
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
MX2018014023A (es) 2019-04-04
US20190248852A1 (en) 2019-08-15
AU2017269496B2 (en) 2021-03-25
PH12018502465A1 (en) 2019-04-08
JP2019520333A (ja) 2019-07-18
WO2017202936A1 (en) 2017-11-30
JP7013390B2 (ja) 2022-01-31
MA45113A (fr) 2019-04-10
PE20190117A1 (es) 2019-01-16
IL262926A (en) 2018-12-31
EP3463412A1 (en) 2019-04-10
KR20190008290A (ko) 2019-01-23
CN109414471A (zh) 2019-03-01
CO2018012258A2 (es) 2018-11-30
BR112018072034A2 (pt) 2019-02-12
CA3025251A1 (en) 2017-11-30
US20210198331A1 (en) 2021-07-01
US12006344B2 (en) 2024-06-11
TW201741333A (zh) 2017-12-01
RU2018141829A (ru) 2020-06-25
CL2018003319A1 (es) 2019-02-01
US20230212245A1 (en) 2023-07-06
RU2018141829A3 (ar) 2020-10-07
AU2017269496A1 (en) 2018-11-15
KR102433503B1 (ko) 2022-08-18

Similar Documents

Publication Publication Date Title
SA518400460B1 (ar) مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
WO2015191781A3 (en) Apelin polypeptides
MX2017014035A (es) Formas solidas novedosas.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
MY197561A (en) Composition for increasing expression of pgc-1?
JOP20210295A1 (ar) أشكال صلبة لمثبط GlyT1
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015001541A3 (en) Pharmaceutical film composition
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.